V
Vivek Roy
Researcher at Mayo Clinic
Publications - 244
Citations - 10969
Vivek Roy is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 51, co-authored 220 publications receiving 9807 citations. Previous affiliations of Vivek Roy include Society of Hospital Medicine & University of Oklahoma Health Sciences Center.
Papers
More filters
Journal ArticleDOI
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Robert C. Flanigan,Sydney E. Salmon,Brent A. Blumenstein,Scott I. Bearman,Vivek Roy,Patrick C. McGrath,John R. Caton,Nikhil C. Munshi,E. David Crawford +8 more
TL;DR: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.
Journal ArticleDOI
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji Kumar,Joseph R. Mikhael,Francis K. Buadi,David Dingli,Angela Dispenzieri,Rafael Fonseca,Morie A. Gertz,Philip R. Greipp,Suzanne R. Hayman,Robert A. Kyle,Martha Q. Lacy,John A. Lust,Craig B. Reeder,Vivek Roy,Stephen J. Russell,Kristen Detweiler Short,A. Keith Stewart,Thomas E. Witzig,Steven R. Zeldenrust,Robert J. Dalton,S. Vincent Rajkumar,P. Leif Bergsagel +21 more
TL;DR: This set of recommendations represents the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
Journal ArticleDOI
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Shaji Kumar,Angela Dispenzieri,Martha Q. Lacy,Suzanne R. Hayman,Francis K. Buadi,Dennis A. Gastineau,Mark R. Litzow,R Fonseca,Vivek Roy,S V Rajkumar,Morie A. Gertz +10 more
TL;DR: A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age, and there was no effect on quality of PBSC collected based on similar engraftment across all groups.
Journal ArticleDOI
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy,Suzanne R. Hayman,Morie A. Gertz,Angela Dispenzieri,Francis K. Buadi,Shaji Kumar,Philip R. Greipp,John A. Lust,Stephen J. Russell,David Dingli,Robert A. Kyle,Rafael Fonseca,Leif Bergsagel,Vivek Roy,Joseph R. Mikhael,A. Keith Stewart,Kristina Laumann,Jacob B. Allred,Sumithra J. Mandrekar,S. Vincent Rajkumar +19 more
TL;DR: The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents.
Journal ArticleDOI
Outcome of transplantation for myelofibrosis
Karen K. Ballen,Smriti Shrestha,Kathleen A. Sobocinski,Mei-Jie Zhang,Asad Bashey,Brian J. Bolwell,Francisco Cervantes,Steven M. Devine,Robert Peter Gale,Vikas Gupta,Theresa Hahn,William J. Hogan,Kröger N,Mark R. Litzow,David I. Marks,Richard T. Maziarz,Philip L. McCarthy,Gary J. Schiller,Harry C. Schouten,Vivek Roy,Peter H. Wiernik,Mary M. Horowitz,Sergio Giralt,Mukta Arora +23 more
TL;DR: In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.